Upcoming PCAC Meeting: What the July 2026 Review Means for Compounded Peptides
Medically reviewed by Dr. Michael Koehler, MD
The Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet on July 23–24, 2026, at the FDA’s White Oak Campus. This public advisory committee meeting will evaluate seven peptides for potential inclusion on the FDA’s Section 503A Bulk Drug Substances List.
This is one of the most significant regulatory developments for peptide therapies in years. Here’s what’s on the agenda, which peptides are under review, and what it could mean for patients and practitioners.
Background: Why This Meeting Matters
In 2023, the FDA removed or restricted many peptides from the 503A compounding list, placing several in Category 2 (substances with significant safety concerns). This effectively limited or halted legal compounding of these substances by licensed pharmacies for human use, pushing much of the market into unregulated “research chemical” channels.
In April 2026, the FDA removed 12 peptides from Category 2 after nominators withdrew their submissions. At the same time, the agency announced PCAC meetings to formally review whether these substances meet the criteria for safe compounding under Section 503A (patient-specific prescriptions from licensed compounding pharmacies).
The July 2026 meeting is the first major step in this review process. A follow-up meeting is expected before February 2027 for additional peptides.
Peptides Under Review at the July 23–24, 2026 PCAC Meeting
July 23, 2026
The committee will discuss:
BPC-157 (free base and acetate forms) - Proposed uses include ulcerative colitis, wound healing, and inflammatory conditions.
KPV (free base and acetate forms) - Proposed uses include wound healing and inflammatory conditions.
TB-500 (Thymosin Beta-4 fragment, free base and acetate) - Proposed uses include wound healing.
MOTS-c (free base and acetate) - Proposed uses include obesity and osteoporosis.
July 24, 2026
The committee will discuss:
Emideltide (also known as DSIP / delta sleep-inducing peptide, free base and acetate) - Proposed uses include opioid withdrawal, chronic insomnia, and narcolepsy.
Semax (free base and acetate) - Proposed uses include cerebral ischemia, migraine, trigeminal neuralgia, and certain chronic pain conditions.
Epitalon (free base and acetate) - Proposed uses include insomnia and related indications.
These peptides have gained popularity in wellness, recovery, anti-aging, and performance circles, often based on preclinical data, smaller human studies, or clinical experience. However, most lack large-scale, FDA-approved clinical trials for the proposed indications.
What Inclusion on the 503A Bulks List Would Mean
If the PCAC recommends these peptides and the FDA ultimately adds them to the 503A Bulks List:
Licensed compounding pharmacies could legally prepare them for individual patients under a valid prescription.
This would bring these therapies under regulated compounding standards (quality, sterility, and oversight requirements) rather than the current gray-market “research use only” landscape.
Patients could potentially access these peptides through legitimate medical channels with proper oversight, rather than relying on unregulated sources.
It would represent a meaningful shift toward greater access for peptides that many practitioners and patients have found clinically useful.
Important caveats:
These substances are not FDA-approved drugs. Inclusion on the 503A list would allow compounding but would not grant full drug approval or change their investigational status.
The PCAC provides non-binding recommendations. The FDA makes the final decision.
Safety, purity, and efficacy data will be central to the committee’s discussion. Critics have raised concerns about limited human data and potential risks with some peptides.
Even if approved for compounding, use would still require careful patient selection, informed consent, and appropriate monitoring by a qualified provider.
What This Means for Peptides Overall
This meeting signals a potential reopening of regulated access to several peptides that were previously restricted. It reflects broader policy interest in expanding options within compounding while addressing safety through the formal review process.
For patients and clinics, it could mean:
More consistent, pharmacy-grade supply.
Reduced reliance on overseas or unregulated sources.
Greater opportunity for evidence-informed, individualized protocols under medical supervision.
However, the outcome is not guaranteed. The committee will weigh available safety data, adverse event reports, and clinical utility. The final FDA decision could take months after the July meeting
Our Commitment to Legal and Regulated Peptide Therapies
At Affinity Whole Health, patient safety and full regulatory compliance are non-negotiable. We only offer peptide therapies that are currently legal for compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act.
This means:
We partner exclusively with licensed, FDA-registered compounding pharmacies that adhere to strict quality, sterility, and testing standards.
We never source, recommend, or provide peptides from unregulated “research chemical” vendors, gray-market suppliers, or overseas sources.
All peptide therapies we discuss or prescribe are only offered when they are legally permitted, clinically appropriate, and supported by a valid prescription and ongoing medical supervision.
As the regulatory environment evolves — including the important PCAC review scheduled for July 23–24, 2026 — we will continue to monitor developments closely. If additional peptides are officially added to the 503A Bulks List, we will evaluate them for potential inclusion in our practice only after they become legally available through compliant compounding channels.
Our patients can have complete confidence that any peptide therapy we provide meets the highest standards of legality, quality, and safety.
Stay Informed and Get Personalized Guidance
The regulatory landscape for peptides is evolving rapidly. We are actively monitoring the July 2026 PCAC meeting and will share updates as more information becomes available.
If you’re interested in learning more about peptide therapies, current peptide options, or how we approach regenerative and metabolic health at Affinity Whole Health, we invite you to schedule a consultation. Our team can discuss evidence-based approaches tailored to your goals.
Schedule your consultation today or reach out with any questions — we’re here to help you navigate these developments with clarity and care.
Sources include official FDA announcements and Federal Register notices regarding the July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting.
Important Disclaimer: This blog post is for informational purposes only and does not constitute medical advice. None of the peptides discussed are FDA-approved for the indications mentioned. Decisions about any therapy should be made in consultation with a qualified healthcare provider who can assess individual risks, benefits, and appropriateness.